Liu GY, Budinger GRS, Dematte JE (2022) Advances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. BMJ (Clinical research ed) 377:e066354. https://doi.org/10.1136/bmj-2021-066354

Article  PubMed  Google Scholar 

Schäfer SC, Funke-Chambour M, Berezowska S (2020) Idiopathische Lungenfibrose – Epidemiologie Ursachen und klinischer Verlauf [Idiopathic pulmonary fibrosis-epidemiology causes, and clinical course]. Pathologe 41(1):46–51. https://doi.org/10.1007/s00292-019-00747-x

Article  PubMed  Google Scholar 

Maher TM, Bendstrup E, Dron L, Langley J, Smith G, Khalid JM, Patel H, Kreuter M (2021) Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res 22(1):197. https://doi.org/10.1186/s12931-021-01791-z

Article  PubMed  PubMed Central  Google Scholar 

Raghu G, Chen SY, Yeh WS, Maroni B, Li Q, Lee YC, Collard HR (2014) Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older incidence prevalence and survival 2001–11 The Lancet. Respir Med 2(7):566–572. https://doi.org/10.1016/S2213-2600(14)70101-8

Article  Google Scholar 

Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ et al (2016) Acute Exacerbation of Idiopathic Pulmonary Fibrosis An International Working Group Report. Am J Respir Crit Care Med 194(3):265–275. https://doi.org/10.1164/rccm.201604-0801CI

Article  CAS  PubMed  Google Scholar 

Spagnolo P, Kropski JA, Jones MG, Lee JS, Rossi G, Karampitsakos T, Maher TM, Tzouvelekis A, Ryerson CJ (2021) Idiopathic pulmonary fibrosis: Disease mechanisms and drug development. Pharmacol Therapeut 222:107798. https://doi.org/10.1016/j.pharmthera.2020.107798

Article  CAS  Google Scholar 

Lederer DJ, Martinez FJ (2018) Idiopathic Pulmonary Fibrosis. N Engl J Med 19:1811–1823. https://doi.org/10.1056/NEJMra1705751

Article  Google Scholar 

Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M et al (2010) Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 35(4):821–829. https://doi.org/10.1183/09031936.00005209

Article  CAS  PubMed  Google Scholar 

King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Sussman A, Swigris R, Noble JJ, PW, et al (2014) ASCEND Study GroupA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370(22):2083–2092. https://doi.org/10.1056/NEJMoa1402582

Article  CAS  PubMed  Google Scholar 

Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D et al (2011) Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377(9779):1760–1769. https://doi.org/10.1016/S0140-6736(11)60405-4

Article  CAS  PubMed  Google Scholar 

Richeldi L, Cottin V, du Bois RM, Selman M, Kimura T, Bailes Z et al (2016) Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS(®) trials. Respir Med 113:74–79. https://doi.org/10.1016/j.rmed.2016.02.001

Article  PubMed  Google Scholar 

Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U et al (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370(22):2071–2082. https://doi.org/10.1056/NEJMoa1402584

Article  CAS  PubMed  Google Scholar 

Freemantle N, Strack T (2010) Real-world effectiveness of new medicines should be evaluated by appropriately designed clinical trials. J Clin Epidemiol 63(10):1053–1058. https://doi.org/10.1016/j.jclinepi.2009.07.013

Article  PubMed  Google Scholar 

Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL et al (2016) Real-world evidence what is it and what can it tell us. N Engl J Med 375(23):2293–2297. https://doi.org/10.1056/NEJMsb1609216

Article  PubMed  Google Scholar 

Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta analyses the PRISMA statement. PLoS Med 6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097

Article  PubMed  PubMed Central  Google Scholar 

Fedorov (2008) Get Data Graph Digitizer. Data & Software. https://www.getdata-graph-digitizer.com/index.php. Accessed 26 June 2024

Slim K, Nini E, Forestier D et al (2003) Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ j surg 73(9):712–716. https://doi.org/10.1046/j.1445-2197.2003.02748.x

Article  PubMed  Google Scholar 

Wells GA, Wells G, Shea B, et al (2014) The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. https://doi.org/10.1006/bioe.2002.0137

StataCorp LP (2019) Inventorstata Statistical Software: Release 16. Timberlake Consultants.

Kim J, Chung C, Cho HS, Kim HC (2023) Factors associated with dose reduction of pirfenidone in patients with idiopathic pulmonary fibrosis: a study based on real-world clinical data. PLoS ONE 18(2)

Hwang H, Lee JK, Choi SM, Lee YJ, Cho YJ, Yoon HI et al (2022) Efficacy of lower dose pirfenidone for idiopathic pulmonary fibrosis in real practice a retrospective cohort study. Korean J Intern Med 37(2):366–376. https://doi.org/10.3904/kjim.2020.559

Article  CAS  PubMed  Google Scholar 

Song MJ, Moon SW, Choi JS, Lee SH, Lee SH, Chung KS et al (2020) Efficacy of low dose pirfenidone in idiopathic pulmonary fibrosis real world experience from a tertiary university hospital. Sci Rep 10(1):21218. https://doi.org/10.1038/s41598-020-77837-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kang J, Chung MP, Park MS, Oh IJ, Lee HB, Kim YW et al (2023) Clinical outcomes of dose modification during pirfenidone treatment for IPF: A nationwide post-marketing surveillance study. Front. Pharmacol 13:1025947. https://doi.org/10.3389/fphar.2022.1025947

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dhooria S, Agarwal R, Sehgal IS, Prasad KT, Muth V, Garg M, Bal A, Aggarwal AN, Behera D (2020) A real-world study of the dosing and tolerability of pirfenidone and its effect on survival in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis : Official Journal of WASOG 37(2):148–157. https://doi.org/10.36141/svdld.v37i2.8718

Article  Google Scholar 

Ogawa K, Miyamoto A, Hanada S, Takahashi Y, Murase K, Mochizuki S et al (2018) The efficacy and safety of long term pirfenidone therapy in patients with idiopathic pulmonary fibrosis. Intern Med 57(19):2813–2818. https://doi.org/10.2169/internalmedicine.0559-17

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sakayori M, Terada J, Abe M, Hirasawa Y, Suzuki K, Yoshioka K, Tsushima K, Tatsumi K (2019) Differences in tolerability of pirfenidone between elderly and younger patients with idiopathic pulmonary fibrosis. Drug Des Devel Ther 13:2295–2303. https://doi.org/10.2147/DDDT.S208733

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chung MP, Park MS, Oh IJ, Lee HB, Kim YW, Park JS et al (2020) Safety and efficacy of pirfenidone in advanced idiopathic pulmonary fibrosis a nationwide post-marketing surveillance study in Korean patients. Adv Ther 37(5):2303–2316. https://doi.org/10.1007/s12325-020-01328-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yoon HY, Kim DS, Song JW (2019) Efficacy and safety of pirfenidone in advanced idiopathic pulmonary fibrosis. Respiration international review of thoracic diseases 97(3):242–251. https://doi.org/10.1159/000492937

Article  CAS  PubMed  Google Scholar 

Coşkun F, Çilli A, Hanta İ, Sevinç C, Ödemiş A, Ursavaş A (2021) Evaluation of efficacy and safety of pirfenidone 200 mg tablets in patients with idiopathic pulmonary fibrosis in a real-life setting. Turk J Med Sci 51(6):3082–3088. https://doi.org/10.3906/sag-2102-262

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ogura T, Azuma A, Inoue Y, Taniguchi H, Chida K, Bando M et al (2015) All case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis. Respir Investig 53(5):232–241. https://doi.org/10.1016/j.resinv.2015.06.001

Article  PubMed  Google Scholar 

Oltmanns U, Kahn N, Palmowski K, Träger A, Wenz H, Heussel CP et al (2014) Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases. Respiration 88(3):199–207. https://doi.org/10.1159/000363064

Article  CAS